Cargando…
Current State of Immunotherapy for Treatment of Glioblastoma
At this time, there are no FDA-approved immune therapies for glioblastoma (GBM) despite many unique therapies currently in clinical trials. GBM is a highly immunosuppressive tumor and there are limitations to a safe immune response in the central nervous system. To date, there have been several fail...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer US
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394457/ https://www.ncbi.nlm.nih.gov/pubmed/30790064 http://dx.doi.org/10.1007/s11864-019-0619-4 |